Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no serious side effects. The FDA granted Fast Track status to VERVE-102, and Eli Lilly plans to start Phase 2 trials by year-end. This development could replace chronic cholesterol treatments with a single infusion, marking a significant advance in cardiovascular medicine.
Eli Lilly reported Phase III data for its weight loss drug retatrutide showing strong dose-dependent efficacy, with up to 30% weight loss at 104 weeks in patients with BMI over 35. UBS analysts highlight the drug's potential to differentiate itself i...
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
Eli Lilly's Phase 1b Heart-2 trial showed that a single intravenous dose of VERVE-102 significantly lowered PCSK9 protein and LDL cholesterol (LDL-C) in patients at high risk for cardiovascular disease, with reductions lasting up to 18 months. The tr...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers...
